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Abstract
Acute leukemia, the most common form of cancer in children, accounts for approximately 30% of
all childhood malignancies, with acute lymphoblastic leukemia being five times more frequent than
acute myeloid leukemia. Lineage switch is the term that has been used to describe the phenomenon
of acute leukemias that meet the standard French-American-British system criteria for a particular
lineage (either lymphoid or myeloid) upon initial diagnosis, but meet the criteria for the opposite
lineage at relapse. Many reports have documented conversions of acute lymphoblastic leukemia to
acute myeloid leukemia.
Here, we report the case of a 4-year-old child with acute myeloid leukemia, which upon relapse
switched to acute lymphoblastic leukemia. The morphologic, phenotypic, and molecular features
suggest the origin of a new leukemic clone.
Introduction
Leukemia is a group of malignant diseases of the hemat-
opoietic system characterized by the uncontrolled over-
production of either immature (acute leukemia) or
terminally differentiated (chronic leukemia) leukocytes.
Acute leukemia, the most common form of cancer in chil-
dren, accounts for approximately 30% of all childhood
malignancies [1]. A frequency of ≥ 20% blasts is required
to confirm a diagnosis of acute leukemia. The first com-
prehensive morphologic classification system for acute
leukemias was the French-American-British (FAB) classifi-
cation, which was established in 1976 and revised in
1985. Other recommended tests are immunophenotyp-
ing, cytogenetics, and molecular genetics tests [2].
Acute leukemias can be further sub classified by determin-
ing whether the malignant leukocytes are of myeloid ori-
gin (cells of granulocyte, monocyte, erythroid, or
megakaryocyte lineage) or lymphoid origin (B-cells, T-
cells) [3].
Overall survival for patients with acute lymphoblastic
leukemia is approximately 80%; currently for acute mye-
loid leukemia (AML), most large studies show a five-year
event-free-survival rate of almost 50%, despite the fact
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that between one third and one half of patients with AML
experience relapse, and no standard therapy is recognized
for patients with relapsed and/or refractory AML. Relapses
mostly exhibit the same FAB subtype. Patients with
relapsed/refractory AML usually respond less well and for
a shorter duration to reinduction therapies. This clearly
points to the induction of drug-resistant mechanisms and
is, in part, related to specific chromosomal abnormalities
and the duration of the first remission [4,5].
However, unexplained variability in clinical course still
exists among some individuals within defined risk-group
strata.
"Lineage switch" is the term that has been used to describe
the phenomenon of acute leukemias that meet standard
FAB criteria for a lineage (lymphoid or myeloid) at initial
diagnosis but upon relapse meet the criteria for the oppo-
site lineage [6].
Most reports of lineage switching have demonstrated
acute lymphoblastic leukemia (ALL) to acute myeloid
leukemia (AML) conversions [7-9]. The prognosis for
these patients is variable, and there is no standard treat-
ment for them.
Case presentation
A 4-year-old Mexican Mestizo (Hispanic) male was admit-
ted to the Hospital Infantil de México Federico Gómez
presenting a 30-day history of fever, pallor, and enlarged
cervical lymph nodes.
The initial laboratory findings revealed a white blood cell
count of 4,300/mm3, with 16% blasts in the peripheral
blood, 8.8 g/dL hemoglobin, and a platelet count of
49,000/mm3.
Cerebrospinal fluid was negative for blast cells. The bone
marrow was hypercellular, with 64% blasts, which were
large in size and showed low nucleus: cytoplasm ratio,
monocytoid features, and blue-gray cytoplasm; > 80% of
the blast cells were monoblasts, and the rest were prom-
onocytes or monocytes (Figure 1). The surface immu-
nophenotype was CD45+  (91.1%), CD15+  (95.4%),
CD14-/+ (37.7%), CD13+/- (78.5%), HLA-DR+/- (78.5%),
CD22-/+  (42.8%), CD10-  (2.1%) CD19-  (2.5%) CD20-
(0.7%) CD7- (0.07%), CD3-/+ (19.4%), and CD33- (7.9%)
(Figure 2).
Cytochemistry was positive for myeloperoxidase (MPO).
Conventional cytogenetic analysis using direct and 24-
hour unstimulated and unsynchronized cultures revealed
a 46 XY karyotype. A diagnosis of M5 AML was made. The
patient started chemotherapy with a modified MRC-10
protocol: daunorubicin 50 mg/m2 (days 1, 3 & 5); cytara-
bine 100 mg/m2 in a 1-hour infusion every 12 hours
through days 1 to 10; and etoposide 100 mg/m2 in a 4-
hour infusion every 24 hours through days 1 to 5.
Due to oral candidiasis and an episode of sepsis secondary
to Acinetobacter iwofii, the patient was treated with mero-
penem, amphotericin, and fluconazole.
Remission was determined by marrow aspiration with no
blast cells at day 27th after first chemotherapy cycle.
Thirty days after the first course of chemotherapy, a sec-
ond chemotherapy cycle was administered without com-
plications daunorubicin 50 mg/m2  days 1, 3 & 5;
cytarabine 100 mg/m2 in a 1-hour infusion every 12 hours
through days 1 to 4; and etoposide 100 mg/m2 in a 4-hour
infusion every 24 hours through days 1 to 5.
A third cycle: etoposide 100 mg/m2 in a 4-hour infusion
every 24 hours on days 1-5 and cytarabine 1000 mg/m2 in
a 1-hour infusion every 12 hours (days 1-3) was stopped
on day 3 because of a life-threatening episode of pneumo-
nia; the patient was transferred to the ICU and supported
by mechanical ventilation. Because a lung CT scan
showed features of a right lung abscess, a medium and
right lobectomy was performed.
Upon clinical and hematologic recovery, the patient
received a fourth cycle of chemotherapy with mitox-
antrone 10 mg/m2 in a 1-hour infusion every 24 hours
(days 1-5) and cytarabine 1000 mg/m2 in a 1-hour infu-
sion every 12 hours (days 1-3). Two weeks later, an
Bone marrow aspiration at AML diagnosis Figure 1
Bone marrow aspiration at AML diagnosis. Blast cells 
were large in size and had a low nucleus:cytoplasm ratio, 
monocytoid aspect, and blue-gray cytoplasm. Wright stain, 
1000×.Cases Journal 2009, 2:154 http://www.casesjournal.com/content/2/1/154
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episode of fever, along with neutropenia and mucositis,
was recorded, and the patient was treated with cefepime
and amikacin.
The patient received a fifth cycle or chemotherapy: etopo-
side 100 mg/m2 in a 4-hour infusion every 24 hours for 5
days and cytarabine 1000 mg/m2 in a 1-hour infusion
every 12 hours for 3 days.
Seven months later, after the diagnosis, the chemotherapy
protocol was completed with a clearance of blast cells.
Two months later, the patient presented at the hospital
with petechiae. Initial laboratory data revealed a white
blood cell count of 7,700/mm3, 13% blast cells, 13.7 g/dL
hemoglobin, and a platelet count of 33,000/mm3. The
marrow was hypercellular and contained 85% blasts. In
contrast to the previous neoplasm, the blasts in the cur-
rent specimen were smaller, with a predominance of
small cells, scanty cytoplasm, moderate cytoplasmic
basophilia, and variable cytoplasmic vacuolation (Figure
3), along with the immunophenotype CD45+ (81.6%),
CD10+ (77%), CD19+ (89%), CD22- (0%), CD20- (3.7%),
CD15- (0%), CD14- (4.5%), CD7- (7.8%), CD3- (13.1%),
CD13- (0.27%), CD33- (0.62%), and HLA-DR-  (0.2%)
(Figure 4). These lymphoblasts were negative for mye-
loperoxidase (data not shown).
The patient was diagnosed with pro-B lymphoblastic
leukemia. Cytogenetic studies performed on the marrow
aspirate revealed a karyotype of 46 XY.
We tried to induce remission with the national protocol
for acute lymphoblastic leukemias, adapted from TOTXV
protocol from St Jude Children's Research Hospital with
vincristine 2 mg/m2 once a week for four weeks, daunoru-
bicin 30 mg/m2 once a week for two weeks, L-asparaginase
10,000 IU/m2 three times a week for a total of nine doses,
and dexamethasone 6 mg/m2 for four weeks. However,
the bone marrow examination on the 14th and 21th days of
induction showed persisting infiltration with 50% blasts,
and the patient remained pancytopenic. After an episode
of fever, abdominal pain, and diarrhea, antibiotic therapy
was conducted.
As the bone marrow examination showed persisting infil-
tration, we indicated cycle 1 and 2 to myeloid leukemia
(described above). This scheme of chemotherapy is used
in our hospital for patients with early relapse or refractory
acute leukemia. After that, the patient had infectious com-
plications, followed by development of tumor lysis syn-
drome and septic shock. Chemotherapy was stopped and
the patient was transferred to the ICU and supported by
mechanical ventilation. After clinical recovery, the bone
marrow showed persisting infiltration with 85% blasts,
and the patient's parents asked for palliative care; the
child was cared for at home for four weeks under the sur-
veillance of a palliative care clinic. Despite supportive
measures, he died six months after the diagnosis of
relapse. No autopsy was authorized by the family.
In order to investigate if a B lymphoid transcription factor
was already expressed at the time of remission of the mye-
loid leukemia, we performed detection of PAX5 (B-cell-
specific activator protein for B cells, including B-lymphob-
lastic neoplasms) [10], in bone marrow biopsy taken at
the end of the first scheme of chemotherapy, when the
patient started surveillance (Figure 5).
Briefly, one marrow biopsies fixed in Bouin's solution
were decalcified, and paraffin-embedded tissue sections
were stained with an antibody against the PAX5. The
immunocytochemistry revealed scanty PAX5 expression.
(Only 15% of cells in the specimen were positive). The
same test was not conducted at relapse because no
autopsy was performed.
Discussion
Lineage commitment and differentiation to a mature cell
type are considered to be unidirectional and irreversible
processes under physiological conditions. However, a
number of studies with murine models suggest that plas-
ticity is a significant attribute of hematopoietic progeni-
tors, and the process of cell formation is much more
dynamic than previously thought [11]. Lineage switching
is an example of the lineage heterogeneity that exists in
some acute leukemias [12]. The frequency of lineage
switching among patients with acute leukemia that
relapse is estimated to be between 6% and 9% [6].
Some conditions could explain the lineage change at
relapse, being one of them the possibility of a second neo-
plasm, following two or three years of high dose etopo-
side treatment[13]. Our patient received 1,700 mg/m2 of
etoposide in the first chemotherapy cycle, and the relapse
occurred only 2 months after treatment. It is less probable
to develop a secondary leukemia before a latency period
of two years. Another hypothesis to explain immunophe-
notype changes at relapse is clonal selection. This mecha-
nism has been proposed in patients with a persistent TEL-
AML1+ preleukemic/leukemic clone at relapse [14].
We performed karyotype analysis for our patient and did
not find any cytogenetic alteration. In some instances, an
acute leukemia lineage switch may represent the emer-
gence of a new leukemic clone characterized by different
morphology than the observed upon initial diagnosis,
without gene rearrangements upon conversion to another
lineage. Zardo et al. propose that the plasticity and revers-
ibility of modifications affecting chromatin structure are
important in the expression of genes involved in cell fate
decisions and in maintenance of cell-differentiated states.Cases Journal 2009, 2:154 http://www.casesjournal.com/content/2/1/154
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Epigenetic changes in DNA and chromatin, which must
occur to allow accessibility to transcription factors at spe-
cific DNA-binding sites, are regarded as emerging major
players for hematopoietic stem cell lineage differentiation
[15].
Mantadakis et al. [16] described the in vivo conversion of
T-cell acute lymphoblastic leukemia (ALL), with an early
thymocyte immunophenotype and no myeloid markers,
to acute myeloid leukemia (AML). This evidence suggests
that a subset of T-cell leukemias with minimal differenti-
ation can display a relapse as another lineage, AML.
Palomero et al. suggest that the leukemic transformation
may occur in early progenitors and might be influenced
by external and internal clues; they propose mutations in
the NOTCH1 transcription factor as responsible in lineage
switch leukemias [17].
In our patient, lineage markers revealed the emergence of
apparently new lymphoid populations. In this case the
new 'relapse lymphoid clone' was not detected at the
moment of surveillance in between the first and second-
ary diagnosis by investigation of the B related transcrip-
tion factor PAX5. The selection and emergence of chemo-
resistant sub-clones that are undetectable by routine
methods, or selection of a new leukemic clone have been
previously reported by Henderson et al [18], and we can
not ruled out either of this possibilities for our patient.
Studies of normal blood cell development and malignant
transformation of hematopoietic cells have shown that
the correctly regulated expression of stage- and lineage-
specific genes is a key issue in hematopoiesis. The tran-
scription factor PAX5 has been shown to be a B-cell-spe-
cific activator protein and seems to be crucial for B
lymphopoiesis, including B-lymphoblastic neoplasms
[19,20].
Flow cytometry AML at diagnosis Figure 2
Flow cytometry AML at diagnosis. Immunophenotyping 
of leukemic cells by flow cytometric analyses revealed mye-
loid blasts negative for CD10 and CD19 (A) but positive for 
CD13 (B) and CD14 (C).
Bone marrow aspiration at relapse Figure 3
Bone marrow aspiration at relapse. Blasts were smaller, 
with a predominance of small cells, scanty cytoplasm, moder-
ate cytoplasmic basophilia, and variable cytoplasmic vacuola-
tion. Wright stain, 1000×.
Flow cytometry at relapse Figure 4
Flow cytometry at relapse. Flow cytometric analyses of 
leukemic cells at relapse. Blast cells were identified as lym-
phoblasts because the immunophenotype was positive for 
CD10 and CD19 (A) but negative for CD13 and CD14 (B, 
C).
PAX5 expression in bone marrow from pro-B ALL at AML  remission Figure 5
PAX5 expression in bone marrow from pro-B ALL at 
AML remission. Immunohistochemistry for PAX5 was per-
formed on a marrow biopsy. The frequency of PAX5 cells 
was 15% (A, B). PAX5 expression by lymph node germinal 
center cells is shown for control (C, D).
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The immunocytochemistry for PAX5 suggests that at least
at the moment of the clinical remission, there was no
expression of a transcription factor of lymphoid origin,
and between the first and second leukemias, there was a
period of time where there were no data supporting lym-
phoid malignancy until the patient relapsed.
The absence of a lymphoid transcription factor at the
beginning of surveillance suggests that the lineage switch
occurred upon relapse. These data put forward the possi-
bility of de novo lymphoid leukemia after myeloid leuke-
mia. Further studies on the mechanisms of lineage
commitment and differentiation in acute leukemia cases
will help us to understand the cell and molecular biology
of this phenomenon.
Conclusion
Here, we present one case of lineage switch, from AML to
ALL which we consider of great interest due to the impor-
tance of early recognition of the specific leukemic lineage,
and the medical aid necessary for appropriate treatment.
Lineage switching is a rare but well-documented phenom-
enon. The change in morphology, the cell phenotype at
relapse, and the absence of a crucial lymphoid transcrip-
tion factor when the patient was under clinical surveil-
lance all suggest that a lineage switch from AML to ALL
might represent a heterogeneous original clone at the
molecular level or the emergence of a second new leuke-
mic clone that lacks molecular heterogeneity.
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